Rose McNulty

In a presentation at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023, Robert L. Waterhouse Jr, MD, MBA, HSM, chief medical officer at Baylor Scott & White Quality Alliance, discussed the challenges of value-based care implementation and how to overcome them.

Some of the health care transformations that were forced by the COVID-19 pandemic could continue to benefit patients and the health care system, Jacques Sokolov, MD, said during his keynote address at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023.

Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center and professor of oncologic sciences at University of South Florida, discussed the shift to targeted therapies in acute myeloid leukemia (AML).

Eric Lisle, president and CEO of Southeast Primary Care Partners, discusses the importance of comprehensive patient data for primary care practices implementing value-based care.

The American Society for Radiation Oncology (ASTRO) and European Society for Radiotherapy and Oncology (ESTRO) jointly released a clinical guideline on the use of definitive local therapy for the treatment of oligometastatic non–small cell lung cancer (NSCLC).

The National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023 will highlight topics in value-based care from a business standpoint and managed care decision-making across a host of disease settings on April 27-28 in Orlando, Florida.

Jacque Sokolov, MD, president and chairman at SSB Solutions, previews his keynote presentation and discusses the unique, shifting health care atmosphere leading into the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023.

A recent study found that the majority of interventional phase 3 trials lacked a clear definition of high-risk multiple myeloma, and many patients were missing important data for risk stratification.

The use of active surveillance for indolent prostate cancer cases continues to rise in the United States, but rates of use are lower in minority groups, low-income groups, and patients in rural areas, a recent study found.

Adding motixafortide to standard stem cell mobilization therapy for autologous hematopoietic stem cell transplantation (ASCT) significantly improved collection success rates vs standard therapy plus a placebo in a phase 3 trial of patients with multiple myeloma.

Coverage from the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit.

The review aimed to characterize the impacts of clinical response, delayed disease progression, and lines of therapy on health-related quality of life (HRQOL) for patients with multiple myeloma.

A post-hoc analysis of the EMPOWER-Lung 1 and 3 studies demonstrates long-term survival and responses for patients with locally advanced non–small-cell lung cancer (NSCLC) treated with cemiplimab.

Estimated rates of lung cancer screening with low-dose CT were extremely low among eligible patients across insurance types in 2017, with rates varying between patient demographics.

Chimeric antigen receptor (CAR) T-cell therapies have shown efficacy and safety for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), but barriers to referral may obstruct patient access to them.

A secondary analysis of the phase 3 TOURMALINE-MM4 trial found that ixazomib as postinduction maintenance therapy for multiple myeloma produced a progression-free survival (PFS) benefit vs a placebo across age and frailty subgroups.

A study of patients with acute myeloid leukemia (AML) in first remission found that the presence of certain variants indicative of measurable residual disease ahead of allogeneic hematopoietic cell transplant (HCT) was associated with relapse and worse survival.

A white paper published by the Institute for Clinical and Economic Review (ICER) established a series of recommendations and guidelines for health technology assessment that aim to address health care disparities.

Exposure to pets during fetal development or early infancy was associated with reduced instances of food allergies in young children, with different pet exposures potentially reducing the incidence risk of certain allergen types.

Patients who underwent sublobar resection and those who underwent more invasive lobectomy for early-stage non–small cell lung cancer (NSCLC) showed similar overall and disease-free survival outcomes in a recent study.

Treatment with relugolix and concomitant therapies for prostate cancer showed similar safety and efficacy to relugolix alone in a recent study.

Assessing both physical and emotional functioning scales within cancer quality-of-life questionnaires at diagnosis may help predict survival in patients with lung cancer, a recent study found.

Idecabtagene vicleucel (ide-cel) led to significantly longer PFS and better therapy responses than standard regimens for patients with triple-class–exposed relapsed and refractory multiple myeloma.

A review based on an expert panel discussion highlights a need for the inclusion of older patients in studies of immune checkpoint inhibitors for the first-line treatment of advanced non–small cell lung cancer (NSCLC).

Patients with prostate cancer who were treated with brachytherapy boost showed improved survival compared with those treated with external beam radiotherapy in a recent study.

A recent study suggests that sleeve lobectomy is safe to perform in patients with non–small cell lung cancer who received neoadjuvant therapy.

A recent study found that infection is a significant burden in patients with multiple myeloma who receive bispecific antibodies, and viral infections are the most common culprits.

The survival benefits of immune checkpoint inhibitors varied in young patients versus older patients with advanced non–small-cell lung cancer, a recent study found.

A prespecified overall survival analysis of the phase 3 ZUMA-7 trial found that axicabtagene ciloleucel (axi-cel) led to better outcomes vs the historical standard of care for relapsed or refractory large B-cell lymphoma (R/R LBCL).